Sara Mimi Atmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Mimi Atmani has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Amel Dammene Debbih
Department of Obstetrics and Gynaecology, Ibn-Ziri Hospital, EPH Bologhine, Algiers 16000, Algeria
1 shared publication - Assia Galleze
Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, Houari Boumediene University of Sciences and Technology (USTHB), Algiers 16111, Algeria
1 shared publication - Bouchra Nour El Houda Baiski
Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, Houari Boumediene University of Sciences and Technology (USTHB), Algiers 16111, Algeria
1 shared publication - Faiza Bouldjennet
Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Sciences and Technology Houari Boumediene, PB 32, El Alia, Bab Ezzouar, Algiers 16111, Algeria
1 shared publication - Fatma Zohra Ider
Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, Houari Boumediene University of Sciences and Technology (USTHB), Algiers 16111, Algeria
1 shared publication - Fatma Zohra Souid
Immunology Department, Mohamed Seghir Nekkache Hospital, Algiers 16000, Algeria
1 shared publication
Latest Publications
- Open Access
Phosphorylated Neurofilament Heavy Chain in Cerebrospinal Fluid and Serum as a Biomarker of Axonal Injury in Algerian Patients with Multiple Sclerosis
Objective: Axonal injury is a key determinant in irreversible disability in multiple sclerosis (MS). Reliable biomarkers of neuroaxonal damage are essential for improving diagnosis, monitoring disease progression, and evaluating treatment response. This study investigated the relationship between phosphorylated neurofilament heavy chain (pNF-H), clinical characteristics, and conventional cerebrospinal fluid (CSF) and serum biomarkers in Algerian patients with MS. Methods: A total of 102 participants were enrolled. Clinical, immunological, and biochemical parameters were assessed, including the Expanded Disability Status Scale (EDSS), oligoclonal bands (OCBs), IgG index, albumin quotient, and pNF-H concentrations in paired CSF and serum samples. Results: OCBs were detected in 85.5% of patients, and 65.21% exhibited intrathecal immunoglobulin synthesis, with a median IgG index of 0.87. Patients with progressive MS were significantly older and more disabled than those with relapsing–remitting MS (age: p = 0.01; EDSS: p = 0.0007). OCB-positive patients had significantly higher IgG index values (p = 0.0004), but OCB status was not associated with age, EDSS, or albumin quotient. EDSS correlated positively with age (p = 0.0007), albumin quotient (p = 0.01), and IgG index (p = 0.001). Both CSF and serum pNF-H levels were significantly elevated in MS patients compared with NSDs group (p < 0.001). Increased pNF-H concentrations were associated with progressive disease and greater disability (EDSS ≥ 5). Conclusions: Elevated pNF-H levels in CSF and serum are associated with disease severity and progressive MS, supporting their potential as complementary biomarkers of neuroaxonal damage and clinical disability in routine MS assessment.
Open AccessPhosphorylated Neurofilament Heavy Chain in Cerebrospinal Fluid and Serum as a Biomarker of Axonal Injury in Algerian Patients with Multiple Sclerosis
Objective: Axonal injury is a key determinant in irreversible disability in multiple sclerosis (MS). Reliable biomarkers of neuroaxonal damage are essential for improving diagnosis, monitoring disease progression, and evaluating treatment response. This study investigated the relationship between phosphorylated neurofilament heavy chain (pNF-H), clinical characteristics, and conventional cerebrospinal fluid (CSF) and serum biomarkers in Algerian patients with MS. Methods: A total of 102 participants were enrolled. Clinical, immunological, and biochemical parameters were assessed, including the Expanded Disability Status Scale (EDSS), oligoclonal bands (OCBs), IgG index, albumin quotient, and pNF-H concentrations in paired CSF and serum samples. Results: OCBs were detected in 85.5% of patients, and 65.21% exhibited intrathecal immunoglobulin synthesis, with a median IgG index of 0.87. Patients with progressive MS were significantly older and more disabled than those with relapsing–remitting MS (age: p = 0.01; EDSS: p = 0.0007). OCB-positive patients had significantly higher IgG index values (p = 0.0004), but OCB status was not associated with age, EDSS, or albumin quotient. EDSS correlated positively with age (p = 0.0007), albumin quotient (p = 0.01), and IgG index (p = 0.001). Both CSF and serum pNF-H levels were significantly elevated in MS patients compared with NSDs group (p < 0.001). Increased pNF-H concentrations were associated with progressive disease and greater disability (EDSS ≥ 5). Conclusions: Elevated pNF-H levels in CSF and serum are associated with disease severity and progressive MS, supporting their potential as complementary biomarkers of neuroaxonal damage and clinical disability in routine MS assessment.
- Open Access
Association of the eNOS Gene Intron 4 VNTR Polymorphism with Susceptibility to Preeclampsia and Its Severity in an Algerian Cohort
Background/Objectives: Preeclampsia (PE) is the primary cause of maternal and perinatal morbidity and mortality on a global scale. It is driven by a multifactorial aetiology, in which genetic factors involved in blood pressure regulation, including the endothelial nitric oxide synthase (eNOS) gene, play an important role. This study aimed to investigate the association between eNOS gene polymorphisms and the development and severity of PE in an Algerian cohort. Methods: A total of 305 Algerian women, comprising 124 patients with PE and 181 healthy controls, were genotyped for two polymorphisms: intron 4 variable number tandem repeat (VNTR) (4a/4b) and the −786 T>C promoter variant. Genotyping was performed using standard polymerase chain reaction (PCR) for VNTR and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) for the −786 T>C variant. Results: Our results revealed no significant difference in the allelic or genotypic frequencies of the −786 T>C polymorphism between the cases and controls (p > 0.05). Interestingly, the frequency of the protective “4b” allele was significantly lower in cases than in controls (odds ratio (OR) = 0.400 [0.278–0.575]; p < 0.0001). However, the “4a” allele and the 4a/4a genotype were significantly associated with an increased risk of preeclampsia (OR = 2.50 [1.74–3.59], p < 0.0001; and OR = 6.20 [2.85-13.50], p < 0.0001, respectively). Furthermore, they were correlated with disease severity (allelic: OR = 2.76 [1.60–4.75], p = 0.0002; and genotypic: OR = 4.64 [1.83-11.78], p = 0.0003). Conclusions: These findings support the potential role of the eNOS VNTR 4a/4b polymorphism in both the risk and severity of preeclampsia in the Algerian population.
Open AccessAssociation of the eNOS Gene Intron 4 VNTR Polymorphism with Susceptibility to Preeclampsia and Its Severity in an Algerian Cohort
Background/Objectives: Preeclampsia (PE) is the primary cause of maternal and perinatal morbidity and mortality on a global scale. It is driven by a multifactorial aetiology, in which genetic factors involved in blood pressure regulation, including the endothelial nitric oxide synthase (eNOS) gene, play an important role. This study aimed to investigate the association between eNOS gene polymorphisms and the development and severity of PE in an Algerian cohort. Methods: A total of 305 Algerian women, comprising 124 patients with PE and 181 healthy controls, were genotyped for two polymorphisms: intron 4 variable number tandem repeat (VNTR) (4a/4b) and the −786 T>C promoter variant. Genotyping was performed using standard polymerase chain reaction (PCR) for VNTR and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) for the −786 T>C variant. Results: Our results revealed no significant difference in the allelic or genotypic frequencies of the −786 T>C polymorphism between the cases and controls (p > 0.05). Interestingly, the frequency of the protective “4b” allele was significantly lower in cases than in controls (odds ratio (OR) = 0.400 [0.278–0.575]; p < 0.0001). However, the “4a” allele and the 4a/4a genotype were significantly associated with an increased risk of preeclampsia (OR = 2.50 [1.74–3.59], p < 0.0001; and OR = 6.20 [2.85-13.50], p < 0.0001, respectively). Furthermore, they were correlated with disease severity (allelic: OR = 2.76 [1.60–4.75], p = 0.0002; and genotypic: OR = 4.64 [1.83-11.78], p = 0.0003). Conclusions: These findings support the potential role of the eNOS VNTR 4a/4b polymorphism in both the risk and severity of preeclampsia in the Algerian population.